REINVENTING MEDICINE FOR A HEALTHIER WORLD
ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company’s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the Company’s website at www.lyndra.com.
At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"
Want to learn more? Please visit our website or contact us at info@lyndra.com.
INSPIRED to Join Our Team? Check us out and apply! www.lyndra.com/join-our-team/
At Lyndra Therapeutics, we are INSPIRED by team members who are excited by innovation and growth, demonstrate strong technical expertise, and live our values. We are looking for people who will bring fresh ideas based on experience and who lead by adapting to the fast pace of an emerging biotech.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $252.5M
Founded date: 2015
Investors 2
Date | Name | Website |
- | Old Silver... | oldsilverv... |
29.06.2021 | Cavendish ... | cavendishf... |
Funding Rounds 5
Date | Series | Amount | Investors |
28.12.2023 | Series E | $101M | - |
27.06.2021 | Series C | $60.5M | - |
30.07.2019 | Grant | $13M | - |
30.01.2019 | Series B | $55M | - |
18.04.2017 | Series A | $23M | - |
Mentions in press and media 22
Date | Title | Description | Source |
28.12.2023 | Lyndra Therapeutics: Clinical-Stage Biopharmaceutical Compan... | Lyndra Therapeutics – a clinical-stage biopharmaceutical company – recently announced the closing of... | pulse2.com... |
21.12.2023 | Lyndra Therapeutics Raises $101M in Series E Funding | Lyndra Therapeutics, a Watertown, MA-based clinical-stage biopharmaceutical company, raised $101M in... | finsmes.co... |
21.12.2023 | Lyndra Therapeutics Closes $101M Series E | WATERTOWN, MA, Lyndra Therapeutics, a clinical-stage biopharmaceutical company, today announced th... | vcnewsdail... |
27.06.2021 | Lyndra Therapeutics Closes $60.5M Series C Financing | Lyndra Therapeutics, a Watertown, Mass.-based clinical-stage biotechnology company pioneering a nove... | finsmes.co... |
25.06.2021 | Does BuzzFeed know what it is? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
25.06.2021 | Does BuzzFeed know what it is? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
24.06.2021 | Lyndra Therapeutics : Completes $60.5 Million Series C Finan... | Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform t... | marketscre... |
30.07.2019 | Lyndra Therapeutics Receives $13M Bill & Melinda Gates F... | Lyndra Therapeutics, a Watertown, MA-based developer of once-monthly oral contraceptive, received a ... | finsmes.co... |
29.01.2019 | Aiming to change the way people take medicine, Lyndra Therap... | A little over two years after Lyndra Therapeutics Inc. first unveiled its technology for time-delaye... | techcrunch... |
29.01.2019 | Lyndra Therapeutics Raises $55M in Series B Financing | Lyndra Therapeutics, a Watertown, MA-based developer of oral, ultra-long-acting, sustained-release t... | finsmes.co... |
Show more